Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVO301 in atopic dermatitis
NCT06723405Phase 2Completed
- Sponsor
- Evommune
- Start
- Feb 2025
- Primary completion
- Nov 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 2 trial of EVO301 in atopic dermatitis (AD), sponsored by Evommune. Started Feb 2025; status: completed.
02
Drugs
EVO301
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06723405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06723405.